Caribou Biosciences, Inc. Earnings Per Share (Basic)
Caribou Biosciences, Inc. (CRBU) reported Earnings Per Share (Basic) of -$0.24 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- Caribou Biosciences, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.24.
- Caribou Biosciences, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.26.
- Caribou Biosciences, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.28.
- Caribou Biosciences, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.30.
- Caribou Biosciences, Inc. earnings per share, basic for fiscal 2025 was -$1.59.
- Caribou Biosciences, Inc. earnings per share, basic for fiscal 2024 was -$1.65.
- Caribou Biosciences, Inc. earnings per share, basic for fiscal 2023 was -$1.38.
- Caribou Biosciences, Inc. earnings per share, basic for fiscal 2022 was -$1.64.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.24 10-Q · filed 2026-08-13 | -$0.50 10-Q · filed 2026-08-13 | -$0.78 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.08 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2026-03-31 | -$0.26 10-Q · filed 2026-05-07 | -$0.54 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.84 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.41 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-12-31 | -$0.28 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$0.58 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$1.15 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.59 10-K · filed 2026-03-05 |
| 2025-09-30 | -$0.30 10-Q · filed 2025-11-12 | -$0.88 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.31 10-Q · filed 2025-11-12 | -$1.70 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-06-30 | -$0.58 10-Q · filed 2026-08-13 | -$1.01 10-Q · filed 2026-08-13 | -$1.40 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.79 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-03-31 | -$0.43 10-Q · filed 2026-05-07 | -$0.82 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.20 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.62 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2024-12-31 | -$0.39 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$0.77 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$1.19 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$1.65 10-K · filed 2026-03-05 |
| 2024-09-30 | -$0.38 10-Q · filed 2025-11-12 | -$0.80 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.26 10-Q · filed 2025-11-12 | -$1.65 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2024-06-30 | -$0.42 10-Q · filed 2025-08-12 | -$0.88 10-Q · filed 2025-08-12 | -$1.27 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.40 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2024-03-31 | -$0.46 10-Q · filed 2025-05-08 | -$0.85 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$0.98 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.43 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2023-12-31 | -$0.39 derived: net income ÷ weighted average shares · filed 2025-03-10 | -$0.52 derived: net income ÷ weighted average shares · filed 2025-03-10 | -$0.95 derived: net income ÷ weighted average shares · filed 2025-03-10 | -$1.38 10-K · filed 2025-03-10 |
| 2023-09-30 | -$0.12 10-Q · filed 2024-11-06 | -$0.54 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$0.98 10-Q · filed 2024-11-06 | -$1.41 derived: net income ÷ weighted average shares · filed 2024-11-06 |
| 2023-06-30 | -$0.48 10-Q · filed 2024-08-06 | -$0.94 10-Q · filed 2024-08-06 | -$1.38 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$1.82 derived: net income ÷ weighted average shares · filed 2024-11-06 |
| 2023-03-31 | -$0.46 10-Q · filed 2024-05-07 | -$0.90 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$1.34 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$1.78 derived: net income ÷ weighted average shares · filed 2024-11-06 |
| 2022-12-31 | -$0.44 derived: net income ÷ weighted average shares · filed 2024-03-11 | -$0.88 derived: net income ÷ weighted average shares · filed 2024-03-11 | -$1.32 derived: net income ÷ weighted average shares · filed 2024-03-11 | -$1.64 10-K · filed 2024-03-11 |
| 2022-09-30 | -$0.44 10-Q · filed 2023-11-07 | -$0.88 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$1.19 10-Q · filed 2023-11-07 | -$1.50 derived: net income ÷ weighted average shares · filed 2023-11-07 |
| 2022-06-30 | -$0.44 10-Q · filed 2023-08-08 | -$0.75 10-Q · filed 2023-08-08 | -$1.06 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$1.50 derived: net income ÷ weighted average shares · filed 2023-11-07 |
| 2022-03-31 | -$0.32 10-Q · filed 2023-05-09 | -$0.62 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$1.05 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$1.64 derived: net income ÷ weighted average shares · filed 2023-11-07 |
| 2021-12-31 | -$0.31 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$0.74 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$1.38 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$2.11 10-K · filed 2023-03-09 |
| 2021-09-30 | -$0.46 10-Q · filed 2022-11-08 | -$1.26 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$2.20 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$1.39 10-Q · filed 2022-08-09 | -$2.78 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |